Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Prenatal Dexamethasone Treatment of Children at Risk for Congenital Adrenal Hyperplasia: The Swedish Experience and Standpoint

Hirvikoski, Tatja, Nordenström, Anna, Wedell, Anna, Ritzén, Martin, Lajic, Svetlana · 2012 · The Journal of Clinical Endocrinology & Metabolism

Abstract

Congenital adrenal hyperplasia (CAH) refers to rare (∼1:10,000), recessively inherited disorders of adrenal steroidogenesis. 21-Hydroxylase deficiency, the most common form, results in virilization of external genitalia in severely affected female fetuses. Prenatal treatment of CAH with dexamethasone (DEX) has been administered since the mid-1980s and is effective in reducing virilization in CAH-affected girls (1). The treatment has to be initiated early in pregnancy, before prenatal testing is possible. Consequently, seven of eight fetuses (all boys and CAH-unaffected girls) are treated in early pregnancy without any benefit of the treatment per se, until prenatal testing can determine the sex and diagnostic status at the end of the first trimester. CAH-affected girls are treated until term. Prenatal DEX treatment of fetuses at risk for CAH is controversial. Results from animal studies, as well as studies on prenatal glucocorticoid therapy in other contexts, have raised concerns regarding possible negative effects on behavioral and somatic development (2, 3). Adult corticosteroid-exposed rodent offspring are characterized by hypertension (via reduced nephron number); hyperinsulinemia and hyperglycemia (via permanently increased levels of the hepatic enzyme phosphoenolpyruvate carboxylase); fatty liver but not obesity when given a high-fat diet; and hyperactivity of the hypothalamic-pituitary-adrenal axis and altered affective behavior, reminiscent of anxiety, as well as impaired learning and memory functions. In the rhesus monkey, prenatal DEX during the last trimester resulted in offspring with elevated basal- and stress-stimulated cortisol at the age of 10 months as well as smaller hippocampal volume. In the African vervet monkey, high-dose DEX exposure (120–200 μg/kg) from midgestation until term resulted in offspring with an exaggerated cortisol response to stress already prepubertally, and adult animals exhibited hypertension, impaired glucose tolerance, and hyperinsulinemia (4). A long-term follow-up of individuals treated prenatally with betamethasone due to a risk of preterm birth shows that 30 yr after exposure the individuals exhibit insulin resistance, particularly in women, and 7% of the adults had elevated basal, morning cortisol levels (5). Other authors consider the prenatal treatment of CAH to be safe (1), but the recent Endocrine Society Guidelines state that such treatment should only be done within the frames of ethically approved clinical studies (6). The prenatal treatment of CAH is considered to be safe in the short-term perspective, although there are few long-term follow-up studies. In Sweden, prenatal treatment of CAH has been administered within the frameworks of a clinical study since 1999. The study, which is ongoing, is designed as a prospective, nonrandomized, multicenter trial in several participating European countries, including both follow-up of the mothers and long-term follow-up of the children. In Sweden, 31 cases have been enrolled during the last 10 yr. Hence, it will take several years before the first results from the long-term follow-up assessments will be available. We have also conducted retrospective follow-up studies of mothers and 43 children treated in Sweden and Norway during 1985–1995 (7–10). In summary, maternal side effects were such as can be expected with glucocorticoid/DEX treatment. Most of the maternal side effects seem to disappear after discontinuation of treatment, but in our experience, approximately 50% of the mothers treated during pregnancy and all mothers treated until term reported some type of discomfort that could be attributed to DEX. In general, treated children were born at term and were not small for gestational age. As a group, they did not exhibit teratogenous effects/gross malformations, although eight severe adverse events were noted in the treated group, compared with one in the control group. Three children failed to thrive during the first year of life; in addition, one of these children had a developmental delay; one had developmental delay and hypospadias; one had hydrocephalus; two girls were born small for gestational age, and one of these girls was later diagnosed with mental retardation; and one child had severe mood fluctuations that caused hospital admission. In the control group, only one child was admitted because of Down's syndrome. In the follow-up studies on the behavioral development of the 40 Swedish children, at a mean age of 11 yr, parent reports indicated good general adaptation, psychological well-being, and school performance in DEX-exposed children compared with nontreated controls. Direct neuropsychological assessments of the children showed normal results on measures of IQ, learning, and memory. However, an adverse effect was observed in the form of impaired verbal working memory in CAH-unaffected short-term-treated cases. The verbal working memory capacity correlated with the children's self-perception of

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2012-1222

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Hirvikoski, T., Nordenström, A., Wedell, A., Ritzén, M., & Lajic, S.
Affiliations
  • Department of Molecular Medicine and Surgery, Centre for Molecular Medicine (T.H., A.N., A.W., S.L.), SE-17176 Stockholm, Sweden
  • Department of Women's and Children's Health (M.R.), Karolinska Institutet/Karolinska University Hospital, SE-17176 Stockholm, Sweden
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2012-06-01
Volume
97
Issue
6
Pages
1881-1883
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2043742190
Cited by
80
References
13
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 2 · 2019: 10 · 2018: 7 · 2017: 5 · 2016: 4 · 2015: 10 · 2014: 6 · 2013: 9 · 2012: 7
FWCI
4.11
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
Keywords
congenital adrenal hyperplasia, prenatal dexamethasone, 21-hydroxylase deficiency, fetal virilization, prenatal testing, hypothalamic-pituitary-adrenal axis, cortisol, insulin resistance, hypertension, glucocorticoid exposure, betamethasone, preterm birth
MeSH terms
Adrenal Hyperplasia, Congenital, Clinical Trials as Topic, Dexamethasone, Female, Glucocorticoids, Humans, Male, Pregnancy, Prenatal Exposure Delayed Effects, Risk Factors, Sweden, Virilism, Multicenter Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.